Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1804, Issue 10, 2010, Pages 1974-1987

  Colavita, Irene ^a,b   Esposito, Nicola ^a,c   Martinelli, Rosanna ^a,c   Catanzano, Francesca ^a,d   Melo, Junia V ^e   Pane, Fabrizio ^a,c   Ruoppolo, Margherita ^a,c   Salvatore, Francesco ^a,c  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b IRCCS SDN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF SANNIO   (Italy)

^e INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

2D differential gel electrophoresis; Bcr Abl; Chronic myeloid leukemia; Imatinib resistance; KCL22 cell

Indexed keywords

ASPARTATE TRANSFER RNA LIGASE; BCR ABL PROTEIN; BETA ACTIN; CARBONATE DEHYDRATASE II; CRK LIKE PROTEIN; CYTOSOL AMINOPEPTIDASE; FERRITIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEMATOPOIETIC CELL KINASE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXIREDOXIN 1; PHOSPHOGLYCERATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PORIN; PROTEIN KINASE LYN; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RAS PROTEIN; SEPTIN; SERINE PROTEINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; TRANSGELIN; TRIOSEPHOSPHATE ISOMERASE; UNINDEXED DRUG;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; GEL ELECTROPHORESIS; MASS SPECTROMETRY; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FUSION PROTEINS, BCR-ABL; GLUTATHIONE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NADP; PIPERAZINES; PROTEOME; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 77956062958     PISSN: 15709639     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbapap.2010.04.009     Document Type: Article

References (88)

1. Deininger M.W.N., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood 2000, 96:3343-3356.
2. Pane F., Intrieri M., Quintarelli C., Izzo B., Muccioli G.C., Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene 2002, 21:8652-8667.
3. Melo J.V., Hughes T.P., Apperley J.F. Chronic myeloid leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2003, 1:132-152.
4. Melo J.V., Deininger M.W.N. Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation. Hematol. Oncol. Clin. North Am. 2004, 18:545-568.
5. Melo J.V., Barnes D.J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 2007, 7:441-453.
6. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
7. Hantschel O., Rix U., Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 2008, 49:615-619.
8. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002, 347:472-480.
9. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., Dimitrijevic S., Mahon F.X., Marin D., Nikolova Z., Olavarria E., Silberman S., Schultheis B., Cross N.C., Goldman G.M. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 2002, 347:481-487.
10. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001, 344:1031-1037.
11. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., Deininger M.W., Silver R.T., Goldman J.M., Stone R.M., Cervantes F., Hochhaus A., Powell B.L., Gabrilove J.L., Rousselot P., Reiffers J., Cornelissen J.J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J.L., Radich J.P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R.A. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 2006, 355:2408-2417. IRIS Investigators.
12. Melo J.V., Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007, 249:121-132.
13. Cang S., Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J. Hematol. Oncol. 2008, 1:1-15.
14. Pane F., Mostarda I., Selleri C., Salzano R., Raiola A.M., Luciano L., Saglio G., Rotoli B., Salvatore F. BCR/ABL mRNA and the P210(BCR/ABL) protein are down-modulated by interferon-alpha in chronic myeloid leukemia patients. Blood 1999, 94:2200-2207.
15. Hochhaus A., Kreil S., Corbin A.S., La Rosée P., Müller M.C., Lahaye T., Hanfstein B., Schoch C., Cross N.C., Berger U., Gschaidmeier H., Druker B.J., Hehlmann R. Molecular and chromosomal mechanisms of resistance to imatinib. Leukemia 2002, 16:2190-2196.
16. Weisberg E., Manley P.W., Cowan-Jacob S.W., Hochhaus A., Griffin J.D. Second generation inhibitors of BCRABL for the treatment of imatinib resistant chronic myeloid leukaemia. Nat. Rev. Cancer 2007, 7:345-356.
17. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J.D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O.G. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. 2006, 354:2542-2551.
18. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S., Cornelius L.A., Das J., Doweyko A.M., Fairchild C., Hunt J.T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G.L., Schmidt R.J., Tokarski J., Wen M.L., Wityak J., Borzilleri R.M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2methylpyrimidinylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 2004, 47:6658-6661.
19. Puttini M., Coluccia A.M., Boschelli F., Cleris L., Marchesi E., Donella-Deana A., Ahmed S., Redaelli S., Piazza R., Magistroni V., Andreoni F., Scapozza L., Formelli F., Gambacorti-Passerini C. In vitro and in vivo Activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant Bcr-Abl+neoplastic cells. Cancer Res. 2006, 66:11314-11322.
20. Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., Goldman J.M., Melo J.V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003, 101:2368-2373.
21. Wu J., Meng F., Kong L.Y., Peng Z., Ying Y., Bornmann W.G., Darnay B.G., Lamothe B., Sun H., Talpaz M., Donato N.J. Association between imatinib-resistant BCR_ABL mutation-negative leukemia and persistent activation of lyn kinase. J. Natl. Cancer Inst. 2008, 100:926-939.
22. Lee F., Fandi A., Voi M. Overcoming kinase resistance in chronic myeloid leukemia. Int. J. Biochem. Cell Biol. 2008, 40:334-343.
23. Roginskaya V., Zuo S., Caudell E., Nambudiri G., Kraker A.J., Corey S.J. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999, 13:855-861.
24. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., Talpaz M. BCR-ABL independence and Lyn kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101:690-698.
25. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., Shishodia S., Albitar M., Hayes K., Kantarjian H., Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64:672-677.
26. Quintás-Cardama A., Kantarjian H.M., Cortes J.E. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16:122-131.
27. Mahon F.X., Deininger M.V.N., Schultheis B., Chabrol J., Reiffers J., Goldman J.M., Melo J.V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96:1070-1079.
28. Ferrari G., Pastorelli R., Buchi F., Spinelli E., Gozzini A., Bosi A., Santini V. Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance. J. Proteome Res. 2007, 6:367-375.
29. Rosenhahn J., Weise A., Michel S., Hennig K., Hartmann I., Schiefner J., Schubert K., Liehr T., Von Eggeling F., Loncarevic V. Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R. Int. J. Oncol. 2007, 31:121-128.
30. Fontana S., Alessandro R., Barranca M., Giordano M., Corrado C., Zanella-Cleon I., Becchi M., Kohn E.C., De Leo G. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines. J. Proteome Res. 2007, 6:4330-4342.
31. Jørgensen H.G., Holyoake T.L. Characterization of cancer stem cells in chronic myeloid leukaemia. Biochem. Soc. Trans. 2007, 35:1347-1351.
32. Miyoshi T., Nagai T., Ohmine K., Nakamura M., Kano Y., Muroi K., Komatsu N., Ozawa K. Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. Biochem. Pharmacol. 2005, 69:1585-1594.
33. Ohmine K., Nagai T., Tarumoto T., Miyoshi T., Muroi K., Mano H., Komatsu H., Takaku F., Ozawa K. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR. Stem Cells 2003, 21:315-321.
34. Park J., Kim S., Oh C., Soo Yoon S., Lee D., Kim Y. Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells. J. Biochem. Mol. Biol. 2005, 38:725-738.
35. Park J., Kim S., Oh C., Soo Yoon S., Lee D., Kim Y. Differential tyrosine phosphorylation of leukemic cells during apoptosis as a results of treatment with imatinib mesylate. Biochem. Biophys. Res. Comm. 2005, 336:942-951.
36. Unwin R.D., Sternberg D.W., Lu Y., Pierce A., Gilliland D.G., Whetton A.D. Global effects of BCR/ABL and TEL/PDGFR? expression on the proteome and phosphoproteome. J. Biol. Chem. 2005, 280:6316-6326.
37. Wetzel R., Goss V.L., Norris B., Popova L., Melnick M., Smith B.L. Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles. J. Immunol. Meth. 2005, 305:59-66.
38. Timms J.F., Cramer R. Difference gel electrophoresis. Proteomics 2008, 8:4886-4897.
39. Montesano Gesualdi M., Chirico G., Pirozzi G., Costantino E., Landriscina M., Esposito F. Tumor necrosis factor-associated protein 1 (TRAP-1) protects cells from oxidative stress and apoptosis. Stress 2007, 10:342-350.
40. Pocaly M., Lagarde V., Etienne G., Dupouy M., Lapaillerie D., Claverol S., Vilain S., Bonneu M., Turcq B., Mahon F.X., Pasquet J.M. Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance. Proteomics 2008, 8:2394-2406.
41. Wang N., Li Z., Ding R., Frank G.D., Senbonmatsu T., Landon E.J., Inagami T., Zhao Z.J. Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signalling. J. Biol. Chem. 2006, 281:21878-21883.
42. Rix U., Hantschel O., Dürnberger G., Remsing Rix L.L., Planyavsky M., Fernbach N.V., Kaupe I., Bennett K.L., Valent P., Colinge J., Köcher T., Superti-Furga G. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 2007, 110:4055-4063.
43. Winger J.A., Hantschel O., Superti-Furga G., Kuriyan J. The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct. Biol. 2009, 9:7.
44. Lee S.J., Wang J.Y. Exploiting the promiscuity of imatinib. J. Biol. 2009, 8:30.
45. Esteso G., Mora M.I., Garrido J.J., Corrales F., Moreno A.J. Proteomic analysis of the porcine platelet proteome and alterations induced by thrombin activation. Proteomics 2008, 71:547-560.
46. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W., Chang F., Lehmann B., Terrian D.M., Milella M., Tafuri A., Stivala F., Libra M., Basecke J., Evangelisti C., Martelli A.M., Franklin R.A. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007, 1773:1263-1284.
47. Ayala A., F-Lobato M., Machado A. Malic enzyme levels are increases by the activation of NADPH-consuming pathways: detoxification processes. FEBS Lett. 1986, 202:102-106.
48. +-dependent isocitrate dehydrogenase and malic enzyme in rabbit lens epithelial cells. Invest. Ophthalmol. Vis. Sci. 1988, 29:821-823.
49. Tipping A.J., Deininger M.W., Goldman J.M., Melo J.V. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate. Exp. Hematol. 2003, 31:1073-1080.
50. Brehme M., Hantschel O., Colinge J., Kaupe I., Planyavsky M., Köcher T., Mechtler K., Bennett K.L., Superti-Furga G. Charting the molecular network of the drug target Bcr-Abl. Proc. Natl. Acad. Sci. USA 2009, 106:7414-7419.
51. Celli C.M., Tran N., Knox R., Jaiswal A.K. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem. Pharmacol. 2006, 72:366-376.
52. Rix U., Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 2009, 5:616-624.
53. Remsing R.L.L., Rix U., Colinge J., Hantschel O., Bennett K.L., Stranzl T., Müller A., Baumgartner C., Valent P., Augustin M., Till J.H., Superti-Furga G. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, 23:477-485.
54. Rodrigues M.S., Reddy M.M., Sattler M. Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications. Antioxid. Redox Signal. 2008, 10:1813-1848.
55. Tarumoto T., Nagai T., Ohmine K., Miyoshi T., Nakamura M., Kondo T., Mitsugic K., Nakano S., Muroi K., Komatsu N., Ozawa K. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp. Hematol. 2004, 32:375-381.
56. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin. Pharmacokinet. 2005, 44:349-366.
57. Haddad J.J. Redox regulation of pro-inflammatory cytokines and IkappaB-alpha/NF-kappaB nuclear translocation and activation. Biochem. Biophys. Res. Commun. 2002, 296:847-856.
58. Ranawat P., Bansal M.P. Decreased glutathione levels potentiate the apoptotic efficacy of selenium: possible involvement of p38 and JNK MAPKs in vitro. Mol. Cell. Biochem. 2008, 309:21-32.
59. Gong X., Gutala R., Jaiswal A.K. Quinone oxidoreductases and vitamin K metabolism. Vitam. Horm. 2008, 78:85-101.
60. Vella F., Ferry G., Delagrange P., Boutin J.A. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 2005, 71:1-12.
61. Bantscheff M., Eberhard D., Abraham Y., Bastuck S., Boesche M., Hobson S., Mathieson T., Perrin J., Raida M., Rau C., Reader V., Sweetman G., Bauer A., Bouwmeester T., Hopf C., Kruse U., Neubauer G., Ramsden N., Rick J., Kuster B., Drewes G. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 2007, 25:1035-1044.
62. Matsuda A., Suzuki Y., Honda G., Muramatsu S., Matsuzaki O., Nagano Y., Doi T., Shimotohno K., Harada T., Nishida E., Hayashi H., Sugano S. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene 2003, 22:3307-3318.
63. Donato N.J., Wu J.Y., Stapley J., Lin H., Arlinghaus R., Aggarwal B.B., Shishodia S., Albitar M., Hayes K., Kantarjian H., Talpaz M. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004, 64:672-677.
64. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
65. Wang X.Z., Grammatikakis N., Siganou A., Stevenson M.A., Calderwood S.K. Interactions between extracellular signal-regulated protein kinase 1, 14-3-3 and heat shock factor 1 during stress. J. Biol. Chem. 2004, 279:49460-49469.
66. Nambu T., Araki N., Nakagawa A., Kuniyasu A., Kawaguchi T., Hamada A., Saito H. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci. 2010, 101:137-142.
67. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000, 11:355-360.
68. Volloch V.Z., Sherman M.Y. Oncogenic potential of Hsp72. Oncogene 1999, 18:3648-3651.
69. Creagh E.M., Sheehan D., Cotter T.G. Heat shock proteins-modulators of apoptosis in tumour cells. Leukemia 2000, 14:1161-1173.
70. Takayama S., Reed J.C., Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003, 22:9041-9047.
71. Nimmanapalli R., O'Bryan E., Huang M., Bali P., Burnette P.K., Loughran T., Tepperberg J., Jove R., Bhalla K. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002, 62:5761-5769.
72. Guo F., Sigua C., Bali P., George P., Fiskus W., Scuto A., Annavarapu S., Mouttaki A., Sondarva G., Wei S., Wu J., Djeu J., Bhalla K. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005, 105:1246-1255.
73. Pocaly M., Lagarde V., Etienne G., Ribeil J.A., Claverol S., Bonneu M., Moreau-Gaudry F., Guyonnet-Duperat V., Hermine O., Melo J.V., Dupouy M., Turcq B., Mahon F.X., Pasquet J.M. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 2007, 21:93-101.
74. Balabanov S., Gontarewicz A., Ziegler P., Hartmann U., Kammer W., Copland M., Brassat U., Priemer M., Hauber I., Wilhelm T., Schwarz G., Kanz L., Bokemeyer C., Hauber J., Holyoake T.L., Nordheim A., Brümmendorf T.H. Hypusination of eukaryotic initiation factor 5A(eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007, 109:1701-1711.
75. Oka T., Yoshino T., Hayashi K., Ohara N., Nakanishi T., Yamaai Y., Hiraki A., Sogawa C.A., Kondo E., Teramoto N., Takahashi K., Tsuchiyama J., Akagi T. Reduction of hematopoietic cell-specific tyrosine phosphatase SHP-1 gene expression in natural killer cell lymphoma and various types of lymphomas/leukemias: combination analysis with cDNA expression array and tissue microarray. Am. J. Pathol. 2001, 159:1495-1505.
76. Wu C., Sun M., Liu L., Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 2003, 306:1-12.
77. Amin H.M., Hoshino K., Yang H., Lin Q., Lai R., Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia. J. Pathol. 2007, 212:402-410.
78. Samanta A.K., Chakraborty S.N., Wang Y., Kantarjian H., Sun X., Hood J., Perrotti D., Arlinghaus R.B. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene 2009, 28:1669-1681.
79. Chen J., Yu W.M., Daino H., Broxmeyer H.E., Druker B.J., Qu C.K. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 2007, 109:778-785.
80. Wang Y., Serfass L., Roy M.O., Wong J., Bonneau A.M., Georges E. Annexin-I expression modulates drug resistance in tumor cells. Biochem. Biophys. Res. Commun. 2004, 314:565-570.
81. Rhee H.J., Kim G.Y., Huh J.W., Kim S.W., Na D.S. Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydrylreactive agent. Eur. J. Biochem. 2000, 267:3220-3225.
82. Alldridge L.C., Bryant C.E. Annexin 1 regulates cell proliferation by disruption of cell morphology and inhibition of cyclin D1 expression through sustained activation of the ERK1/2 MAPK signal. Exp. Cell Res. 2003, 290:93-107.
83. Garcia Pedrero J.M., Fernandez M.P., Morgan R.O., Herrero Zapatero A., Gonzalez M.V., Suarez Nieto C., Rodrigo J.P. Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am. J. Pathol. 2004, 164:73-79.
84. Debret R., El Btaouri H., Duca L., Rahman I., Radke S., Haye B., Sallenave J.M., Antonicelli F. Annexin A1 processing is associated with caspase-dependent apoptosis in BZR cells. FEBS Lett. 2003, 546:195-202.
85. Solito E., De Coupade C., Canaider S., Goulding N.J., Perretti M. Transfection of annexin 1 in monocytic cells produces a high degree of spontaneous and stimulated apoptosis associated with caspase-3 activation. Br. J. Pharmacol. 2001, 133:217-228.
86. Solito E., Kamal A., Russo-Marie F., Buckingham J.C., Marullo S., Perretti M. A novel calcium dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J. 2003, 17:1544-1546.
87. Moriyama K., Yahara I. Human CAP1 is a key factor in the recycling of cofilin and actin for rapid actin turnover. J. Cell Sci. 2002, 115:1591-1601.
88. Hynes G.M., Willison K.R. Individual subunits of the eukaryotic cytosolic chaperonin mediate interactions with binding sites located on subdomains of b-actin. J. Biol. Chem. 2000, 275:18985-18994.